Conversation with The Cancer LetterFree Porter: I can’t tell you how the Trump administration gets its budget numbers March 16, 2018Vol.44 No.11By Paul Goldberg
Clinical RoundupFree Roswell Park ovarian cancer registry data links ovarian and testicular cancer March 09, 2018Vol.44 No.10
Conversation with The Cancer LetterFree BMS’s Farajallah: Opdivo is the only PD-1 inhibitor approved for four-week dosing March 09, 2018Vol.44 No.10By Matthew Bin Han Ong
FreeFunding Opportunities DOD Health Program Anticipated Funding Opportunities for FY 2018 March 09, 2018Vol.44 No.10
FreeIn Brief Wolin named director at Center for Carcinoid and Neuroendocrine Tumors at Mt. Sinai March 09, 2018Vol.44 No.10
FreeIn Brief Cleary named director of IU Walther Supportive Oncology Program March 09, 2018Vol.44 No.10
FreeGuest Editorial Beyond #MeToo:Sexual Harassment in Biomedicine March 09, 2018Vol.44 No.10By Kelly McBride Folkers
Free Beyond morphology:FDA mulls acute lymphoblastic leukemia drug based on elimination of “minimal residual disease” March 09, 2018Vol.44 No.10By Paul Goldberg
Drugs & TargetsFree Lilly receives additional FDA approval for Verzenio for advanced breast cancer March 02, 2018Vol.44 No.09
